New antimalarial drug leads targeting multiple species and life cycle stages

针对多个物种和生命周期阶段的新抗疟药物先导化合物

• 批准号: nhmrc : GNT1142875
• 负责人: Dr Andrew Riches
• 金额: $ 81.85万
• 依托单位: Griffith University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/new-antimalarial-drug-cycle-stages/1348483
• 关键词: New; antimalarial; drug; leads; targeting

Malaria causes ~200 million clinical cases and >430,000 deaths annually. Prevention and treatment relies on drugs, however malaria parasite drug resistance is an enormous problem. To address this issue, and aim towards eliminating malaria, we need to develop new drugs. This project addresses this important health need by investigating the ability of new chemical compounds, developed at CSIRO, to kill human-infecting malaria parasites during different parts of their complicated lifecycles.

疟疾每年造成约2亿临床病例和43万人死亡。预防和治疗依赖于药物，但疟疾寄生虫的抗药性是一个巨大的问题。为了解决这个问题，并以消灭疟疾为目标，我们需要开发新的药物。该项目通过调查CSIRO开发的新化合物在其复杂生命周期的不同阶段杀死人类感染疟疾寄生虫的能力来解决这一重要的健康需求。